Literature DB >> 2562947

AIDS: a syndrome of immune dysregulation, dysfunction, and deficiency.

A S Edelman1, S Zolla-Pazner.   

Abstract

Acquired immune deficiency syndrome (AIDS) is a disease caused by the human immunodeficiency virus (HIV) in which cellular immune functions are severely impaired. Acute infection and subsequent destruction of helper T cells, although occurring readily in cell cultures, do not appear to be the only mechanisms mediating helper T cell loss. Other mechanisms that may account for the loss of helper T cells include: T cell syncytia formation, decreased T cell production, and autoimmune-related destruction of helper T cells. Immune abnormalities seen early in the course of HIV infection include immune hyperactivation and autoimmune phenomena suggestive of immune dysregulation rather than immune deficiency. Many changes in immune function are, in fact, seen in HIV-seropositive patients who possess a normal number of helper T cells. Mechanisms (other than the loss of helper T cells) that may contribute to the immune abnormalities seen in these patients include noninfectious effects of HIV and HIV proteins, effects of HIV on non-T cells, autoimmune-related manifestations of HIV infection, and HIV-induced activation of normal immunosuppressive circuits.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562947     DOI: 10.1096/fasebj.3.1.2562947

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  25 in total

1.  Spontaneous release of interferon as a predictor of clinical evolution in HIV-positive subjects.

Authors:  A Biglino; A Surbone; F Lipani; N Cappello; B Forno; A M Pollono; M Busso; A Pugliese
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

2.  Platelet-activating factor activates HIV promoter in transfected SH-SY5Y neuroblastoma cells and MOLT-4 T lymphocytes.

Authors:  S P Squinto; P Braquet; A L Block; N G Bazan
Journal:  J Mol Neurosci       Date:  1990       Impact factor: 3.444

3.  Frequencies of HIV-reactive B cells in seropositive and seronegative individuals.

Authors:  R H Zubler; L H Perrin; A Doucet; X Zhang; Y P Huang; P A Miescher
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

4.  Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression.

Authors:  A Valentin; W Lu; M Rosati; R Schneider; J Albert; A Karlsson; G N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

5.  Inhibition of lymphoproliferation and protein kinase C by synthetic peptides with sequence identity to the transmembrane and Q proteins of visna virus.

Authors:  C L Ruegg; J E Clements; M Strand
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

Review 6.  Superantigens related to B cell hyperplasia.

Authors:  N M Ponzio; V K Tsiagbe; G J Thorbecke
Journal:  Springer Semin Immunopathol       Date:  1996

Review 7.  Molecular immunopathogenesis of HIV infection.

Authors:  T T Ng; A J Pinching; C Guntermann; W J Morrow
Journal:  Genitourin Med       Date:  1996-12

8.  Chemotactic response of human monocytes to pentapeptide analog derived from immunodeficiency virus protein gp 120.

Authors:  S Spisani; R Gavioli; A L Giuliani; T Cavalletti; M Marastoni; G Balboni; S Salvadori; R Tomatis; S Traniello
Journal:  Inflammation       Date:  1990-02       Impact factor: 4.092

9.  Polyclonal B-cell activation reveals antibodies against human immunodeficiency virus type 1 (HIV-1) in HIV-1-seronegative individuals.

Authors:  T Jehuda-Cohen; B A Slade; J D Powell; F Villinger; B De; T M Folks; H M McClure; K W Sell; A Ahmed-Ansari
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

10.  Expression of interleukin 2 receptors by monocytes from patients with acquired immunodeficiency syndrome and induction of monocyte interleukin 2 receptors by human immunodeficiency virus in vitro.

Authors:  J B Allen; N McCartney-Francis; P D Smith; G Simon; S Gartner; L M Wahl; M Popovic; S M Wahl
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.